Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. A new Whitepaper from Element Biosciences discusses the AVITI24 5D multiomics… Read More
Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More
This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical… Read More
QUANTRO Therapeutics has successfully completed its first 10-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets. After establishing its technology for single- and dual-target screenings at a current capacity of approximately one million compounds per year, QUANTRO has… Read More
What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More
DDW’s Megan Thomas discusses the opportunity in the multi-omics sector by speaking with leading players and looking at the ways in which it can help us tackle disease. Importance of the multi-omics sector Multi-omics describes the crossover application of many high‐throughput screening technologies. These include genomics, transcriptomics, proteomics, metabolomics, epigenomics, glycomics,… Read More
Download this new brochure ‘Multiomic nanopore sequencing solutions: Revolutionising human disease research‘ to maximise the data generated from your valuable research samples. Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms… Read More
Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms and complex processes, which are incompatible with disease research that utilises scarce tissue samples. Download the brochure to learn how multiomic nanopore sequencing can… Read More
Stefanie Dedeurwaerdere is Global Strategy Lead for Pipeline Development in Global Epilepsy & Rare Syndromes at UCB. In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical… Read More
The global ADME toxicology testing market is predicted to generate a revenue of $19.21 billion by 2030, with a growth rate of 10.2%. Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies… Read More
Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. Professor Blackburn began by sharing an overview… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology’s use in drug discovery and bettering our understanding of disease. RA: How does spatial biology enhance our understanding… Read More
AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method… Read More
SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research. SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. Read More
A new Case Study is available, sponsored by Evotec. The study of health and disease through multi-omics research generates vast amounts of interconnected data. Unlocking their secrets requires complex bioinformatic exploration. This analysis is accelerated by a dedicated and flexible software application that is not only reliable and provides… Read More
The study of health and disease through multi-omics research generates vast amounts of interconnected data. Unlocking their secrets requires complex bioinformatic exploration. This analysis is accelerated by a dedicated and flexible software application that is not only reliable and provides reproducible results, but also facilitates collaboration between project investigators… Read More
